Cowen initiated coverage on shares of Avedro (NASDAQ:AVDR) in a research report report published on Monday morning, MarketBeat.com reports. The firm issued an outperform rating and a $20.00 target price on the stock.
Several other equities analysts have also issued reports on AVDR. JPMorgan Chase & Co. started coverage on shares of Avedro in a report on Monday. They set an overweight rating and a $16.00 target price for the company. Leerink Swann started coverage on shares of Avedro in a report on Monday. They set an outperform rating and a $20.00 target price for the company. Six analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus price target of $19.40.
AVDR stock opened at $12.74 on Monday. Avedro has a 52-week low of $10.75 and a 52-week high of $13.65.
Avedro Company Profile
Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.